.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,854,026

« Back to Dashboard

Details for Patent: 5,854,026

Title: Human growth hormone variant having enhanced affinity for human growth hormone receptor at site 1
Abstract:A human growth hormone variant including the set of amino acid substitutions H18A, Q22A, F25A, D26A, Q29A, E65A, K168A, E174A is disclosed. Also disclosed is a nucleic acid encoding this variant, along with a vector including the nucleic acid, a host cell including the vector, and a process for preparing the variant. The variant has enhanced affinity for human growth hormone receptor at site 1.
Inventor(s): Cunningham; Brian C. (Piedmont, CA), Wells; James A. (Burlingame, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Filing Date:Jun 07, 1995
Application Number:08/487,110
Claims:1. An isolated variant of a naturally occurring human growth hormone having a greater affinity for human growth hormone receptor at site 1 than said naturally occurring human growth hormone, said variant comprising the following set of amino acid substitutions:

H18A, Q22A, F25A, D26A, Q29A, E65A, K168A, E174A.

2. The variant of claim 1 wherein said variant is covalently attached to a polyethylene glycol molecule.

3. An isolated nucleic acid encoding a human growth hormone variant having a greater affinity for human growth hormone receptor at site 1 than said naturally occurring human growth hormone, said variant comprising the following set of amino acid substitutions:

H18A, Q22A, F25A, D26A, Q29A, E65A, K168A, E174A.

4. A vector comprising a nucleic acid encoding a human growth hormone variant having a greater affinity for human growth hormone receptor at site 1 than said naturally occurring human growth hormone, said variant comprising the following set of amino acid substitutions:

H18A, Q22A, F26A, D26A, Q29A, E65A, K168A, E174A.

5. A host cell comprising a vector comprising a nucleic acid encoding a human growth hormone variant having a greater affinity for human growth hormone receptor at site 1 than said naturally occurring human growth hormone, said variant comprising the following set of amino acid substitutions:

H18A, Q22A, F25A, D26A, Q29A, E65A, K168A, E174A.

6. A process for preparing a human growth hormone variant comprising:

(a) culturing a host cell comprising a vector comprising a nucleic acid encoding a human growth hormone variant having a greater affinity for human growth hormone receptor at site 1 than said naturally occurring human growth hormone, said variant comprising the following set of amino acid substitutions:

H18A, Q22A, F25A, D26A, Q29A, E65A, K168A, E174A; and

(b) recovering the variant from the culture.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc